NLE Cardiovascular Nursing — Heart Failure and Cardiac DysrhythmiasStudy Notes

Heart failure is a clinical syndrome—not a single disease—in which the cardiac pump fails to deliver sufficient blood volume to meet the body's metabolic demands. The key word is 'syndrome' because patients present with a constellation of symptoms, signs, and laboratory abnormalities resulting from the underlying cardiac dysfunction. According to the 2021 ESC Guidelines adapted for the Philippine context, HF is classified by ejection fraction: HFrEF (reduced EF ≤40%), HFmrEF (mildly reduced EF 41-49%), and HFpEF (preserved EF ≥50%). The most common etiologies in the Philippines include: • Coronary artery disease and post-myocardial infarction remodeling (especially in urban centers with high stress and smoking rates) • Hypertension (extremely prevalent; affects nearly 1 in 3 Filipino adults per Department of Health reports) • Valvular disease (rheumatic heart disease still endemic in some rural populations; congenital defects) • Cardiomyopathy (peripartum cardiomyopathy in women of childbearing age; dilated cardiomyopathy from viral infections or genetic predisposition) • Arrhythmogenic processes and chronic tachycardia When the myocardium is initially damaged or overworked, the body activates three major compensatory mechanisms to maintain cardiac output: 1. SYMPATHETIC NERVOUS SYSTEM ACTIVATION: The failing heart triggers baroreceptors and chemoreceptors to increase sympathetic tone. Catecholamines (epinephrine and norepinephrine) bind to beta-1 adrenergic receptors on cardiac myocytes, increasing heart rate (positive chronotropic effect) and contractility (positive inotropic effect). While this acutely maintains cardiac output, chronic sympathetic activation causes: • Increased myocardial oxygen demand and workload (counterproductive) • Progressive ventricular remodeling and fibrosis • Increased arrhythmia risk • Increased peripheral vascular resistance (afterload), making it harder for the weakened heart to eject blood 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (RAAS) ACTIVATION: Decreased renal perfusion from reduced cardiac output triggers the juxtaglomerular cells in the kidney to release renin. Renin converts angiotensinogen to angiotensin I, which is further converted to angiotensin II by the angiotensin-converting enzyme (ACE). Angiotensin II: • Causes intense vasoconstriction (increases afterload) • Stimulates aldosterone release from the adrenal cortex • Increases sympathetic nervous system activity • Promotes sodium and water retention in the kidney • Triggers inflammatory cascades and myocardial fibrosis Aldosterone increases sodium reabsorption in the collecting duct, drawing water with it osmotically. While this increases preload and temporarily boosts cardiac output (Frank-Starling mechanism), chronic volume expansion causes pulmonary and systemic congestion. 3. VENTRICULAR HYPERTROPHY AND DILATION: The failing ventricle thickens (hypertrophy) in response to increased wall stress, and then progressively dilates. Initially, a larger chamber accommodates increased blood volume (preload), maintaining stroke volume via the Frank-Starling law. However, chronic dilation leads to: • Mitral/tricuspid valve insufficiency (functional regurgitation from annular dilation) • Increased wall stress, worsening ischemia • Progressive remodeling with eccentric (dilated) geometry • Loss of systolic and diastolic function THE CRITICAL SHIFT FROM COMPENSATORY TO MALADAPTIVE: Over months to years, these initially helpful mechanisms become harmful. Chronic sympathetic activation causes cardiomyocyte apoptosis and adverse remodeling. Sustained RAAS activation increases afterload and promotes fibrosis. Excessive preload leads to pulmonary edema and peripheral congestion. This understanding explains why modern HF therapy uses: • Beta-blockers (to block harmful sympathetic effects) • ACE inhibitors and ARBs (to interrupt RAAS) • Diuretics (to reduce excessive preload) • Aldosterone antagonists like spironolactone (to block harmful aldosterone effects) These drugs work against the body's own compensatory responses—a paradigm shift that revolutionized HF treatment and improved survival outcomes.

Left-sided heart failure develops when the left ventricle loses its ability to pump blood effectively into the systemic circulation. The problem is not that blood is not being pumped forward; rather, the weakened LV cannot eject all the blood it receives from the left atrium, which receives blood from the pulmonary veins. THE HEMODYNAMIC CHAIN REACTION: When the LV fails to empty completely, blood backs up into the left atrium. The left atrium, now receiving blood from the pulmonary veins but unable to empty into a congested LV, becomes distended. This increased atrial pressure is transmitted backward through the pulmonary veins into the pulmonary capillaries. When pulmonary capillary hydrostatic pressure exceeds the plasma oncotic pressure (typically when PCWP > 18 mmHg), fluid leaks across the capillary membrane into the interstitial space (pulmonary interstitium) and, if severe, into the alveoli. This is the pathophysiological basis for pulmonary congestion and pulmonary edema. MEMORY AID: "Left = Lungs" Left-sided HF affects the pulmonary circulation; signs and symptoms are primarily respiratory. CLINICAL MANIFESTATIONS OF LEFT-SIDED HF (Pulmonary Congestion): 1. DYSPNEA (Shortness of Breath): • Exertional dyspnea: Breathlessness with minimal activity that previously caused no symptoms. Results from elevated pulmonary capillary pressure reducing pulmonary compliance and triggering dyspneic reflex via pulmonary stretch receptors. • Orthopnea: Severe dyspnea when lying flat. In supine position, blood pools from the lower extremities return to the heart more easily, increasing pulmonary venous return and worsening pulmonary congestion. Patients often prop themselves up with multiple pillows or sit in a chair. • Paroxysmal nocturnal dyspnea (PND): Sudden awakening at night (typically 2-3 hours after falling asleep) with acute, severe dyspnea and a sensation of suffocation. During sleep, the supine position causes fluid redistribution, increasing pulmonary capillary pressure suddenly. The patient must sit up or stand, and symptoms gradually improve. PND is more specific for HF than orthopnea. 2. RESPIRATORY FINDINGS: • Tachypnea: Respiratory rate often >20 breaths/min as the body compensates for hypoxemia and decreased lung compliance. • Crackles (rales): Fine, high-pitched crackling sounds heard predominantly in the lung bases on auscultation. They indicate alveolar edema and fluid in the small airways. Crackles may be absent if the patient is upright and compensating well but reappear or worsen with recumbency. • Wheezing: Sometimes heard and may be mistaken for asthma ("cardiac asthma"). Results from pulmonary edema and bronchial compression from enlarged pulmonary vessels. • Diminished breath sounds: In areas of severe consolidation. 3. COUGH: • Dry cough from airway irritation caused by pulmonary edema, especially when lying down. • Productive cough with frothy, pink sputum (pink frothy sputum or blood-tinged sputum): Indicates frank pulmonary edema. The pink color comes from red blood cells that have leaked into alveoli due to hydrostatic pressure overcoming plasma oncotic pressure. Seeing pink frothy sputum is a sign of severe, acute pulmonary edema—a medical emergency. 4. FATIGUE AND WEAKNESS: • Results from poor cardiac output and tissue hypoxia. • Patients report inability to perform usual activities of daily living (ADLs). 5. CARDIAC FINDINGS: • S3 galop (ventricular gallop): A low-pitched, dull third heart sound heard in early diastole (after S2), best heard at the apex with the patient supine. It results from rapid ventricular filling into a dilated, non-compliant ventricle. While not pathognomonic for HF, S3 is highly suggestive, especially in adults over 40. • Tachycardia: Resting heart rate elevated due to sympathetic activation, typically 90-110 bpm or higher. • Displaced apical impulse: In dilated cardiomyopathy, the enlarged LV apex beat is palpated lateral to the midclavicular line and lower than the 5th intercostal space. • Irregular pulse: May indicate atrial fibrillation, a common complication of HF. 6. CEREBRAL EFFECTS: • Restlessness and anxiety from hypoxemia and sympathetic activation. • Confusion or altered mental status in severe cases (decreased cerebral perfusion). • Insomnia from dyspnea and nocturia. NURSING ASSESSMENT OF LEFT-SIDED HF: Assessment is the foundation of the nursing process and requires systematic data collection aligned with Maslow's hierarchy (physiological needs first). RESPIRATORY ASSESSMENT: • Rate, depth, and effort: Count respiratory rate for a full minute; observe for use of accessory muscles (intercostal retractions, nasal flaring), which indicates respiratory distress. • Auscultate lung fields bilaterally: Document the location and character of abnormal sounds (crackles, wheezes, diminished sounds). • Oxygen saturation: SpO2 by pulse oximetry; note the FiO2 being used. • Sputum: Color, consistency, and amount. Report pink or blood-tinged sputum immediately. CARDIOVASCULAR ASSESSMENT: • Apical pulse: Count for a full minute to assess rate and rhythm. Irregular rhythm suggests dysrhythmia (common in HF, especially AFib). • Blood pressure: Both sitting and standing (orthostatic changes). Note trends. • Peripheral perfusion: Skin color, temperature, capillary refill. • Neck veins: Assess jugular venous distention (JVD), though JVD is more specific for right-sided HF. In LSHF, JVD may be absent. • Auscultate heart sounds: Identify S3 galop, new murmurs, irregular rhythms. FLUID AND WEIGHT ASSESSMENT: • Intake and output: Measure and record all fluid intake (oral, IV, feedings) and output (urine, emesis, stool, wound drainage). • Daily weight: Weigh the patient at the same time each day (ideally early morning after voiding, in the same clothes or hospital gown). A gain of 1 kg (about 2.2 lbs) in one day or 2.5 kg in one week indicates fluid retention and must be reported to the provider. This is a cornerstone of HF self-management. • Assess for edema: Although peripheral edema is more specific for right HF, it can occur in LSHF when both ventricles are affected. MENTAL AND EMOTIONAL STATUS: • Observe level of consciousness and orientation. • Assess for anxiety, restlessness, or confusion. • Note emotional response to symptoms and illness. ACTIVITY AND FUNCTIONAL STATUS: • Ask about ability to perform ADLs, work, or usual activities. • Use a standardized tool such as the New York Heart Association (NYHA) functional classification: - Class I: No symptoms with ordinary activity - Class II: Symptoms with ordinary activity; comfortable at rest - Class III: Symptoms with minimal activity; comfortable only at rest - Class IV: Symptoms at rest; unable to carry out any physical activity LABORATORY AND DIAGNOSTIC FINDINGS (will be covered in detail in a later section): • BNP or NT-proBNP: Elevated (>100 pg/mL for BNP indicates possible HF) • Troponin: May be elevated in acute decompensated HF • Chest X-ray: Cardiomegaly (cardiac silhouette >50% of thoracic width), pulmonary vascular congestion (cephalization of pulmonary blood flow), Kerley B lines (horizontal lines at lung bases from pulmonary edema), pleural effusions • Echocardiogram: Determines ejection fraction and wall motion abnormalities; is the gold standard for HF diagnosis

Right-sided heart failure occurs when the right ventricle loses the ability to pump blood effectively into the pulmonary circulation. Unlike left-sided HF where blood backs up into the lungs, in right-sided HF, blood backs up into the right atrium and subsequently into the systemic venous circulation (superior and inferior vena cava). This leads to systemic venous congestion and peripheral edema. THE HEMODYNAMIC CHAIN REACTION IN RSHF: The RV normally receives blood from the inferior and superior vena cava through the tricuspid valve and pumps it into the pulmonary arteries. When the RV becomes weak or the pulmonary vascular resistance increases, the RV cannot empty effectively. Blood backs up into the right atrium, which distends. Elevated right atrial pressure is transmitted backward through the venae cavae into the systemic venous circulation, causing venous congestion throughout the body. Elevated venous pressure causes fluid to leak from the capillaries into the interstitial space, resulting in peripheral edema. Unlike in left HF where fluid accumulates in the lungs, in right HF, fluid accumulates in dependent areas (feet, legs, sacrum) and in the abdominal organs (liver, GI tract). MEMORY AID: "Right = Rest of the Body" Right-sided HF affects the systemic venous circulation; signs and symptoms are primarily systemic (not respiratory). MAJOR CAUSES OF RIGHT-SIDED HF IN THE PHILIPPINE CONTEXT: 1. LEFT-SIDED HEART FAILURE: The most common cause of RSHF. When the LV fails, pulmonary capillary pressure rises. The RV, pumping against chronically elevated pulmonary vascular resistance, eventually dilates and fails. This is called secondary or reactive RSHF. 2. PULMONARY HYPERTENSION: • From chronic lung disease (COPD, severe asthma, interstitial lung disease)—very prevalent in the Philippines given high rates of smoking and air pollution in urban areas • From chronic hypoxia (at high altitudes, though rare in the Philippines; chronic sleep apnea) • From pulmonary embolism (risk factors: immobility, malignancy, post-op, oral contraceptives) • Idiopathic or primary pulmonary hypertension 3. ACUTE RV INFARCTION: Occlusion of the right coronary artery can damage the RV. These patients present with elevated JVD and hypotension (unlike LSHF which causes hypertension and elevated PCWP). 4. VALVULAR DISEASE: • Tricuspid stenosis or regurgitation • Pulmonary stenosis • Secondary tricuspid regurgitation from RV dilation 5. PULMONARY EMBOLISM: Acute increase in RV afterload; if massive, causes acute RV failure and cardiogenic shock. 6. CHRONIC PULMONARY DISEASE: Cor pulmonale: RV hypertrophy and failure secondary to chronic lung disease. In the Philippines, this is often seen in patients with severe COPD or old tuberculosis (TB) with residual lung fibrosis. 7. CONGENITAL HEART DISEASE: Shunts that overload the RV (atrial septal defect, ventricular septal defect) or increase pulmonary vascular resistance. CLINICAL MANIFESTATIONS OF RIGHT-SIDED HF (Systemic Venous Congestion): 1. PERIPHERAL AND DEPENDENT EDEMA: • Bilateral ankle and leg edema, more pronounced in areas subject to gravity (feet, ankles, lower legs). • In bedridden patients, sacral edema is prominent. • Pitting edema: When pressed with a thumb, the depression remains briefly before slowly filling back in, indicating interstitial fluid accumulation. • Progressing edema can involve the entire lower extremity, genitals, and lower abdomen. 2. WEIGHT GAIN: • From fluid retention; can be rapid (several pounds in days). • Unlike weight from fat, fluid weight is typically sudden and accompanied by edema and other congestion signs. 3. JUGULAR VENOUS DISTENTION (JVD): • Elevation of the jugular venous pulse (JVP), seen as fullness in the neck veins, especially when the patient sits at 45 degrees or lies supine. • Normal JVP extends only to the angle of the mandible or slightly above. • In RSHF, JVP extends high up the neck, and the veins are distended and prominent. • JVD is more specific for RSHF than for LSHF. • Hepatojugular reflux: When the examiner applies gentle pressure over the liver, the JVP rises; this indicates the liver is congested and the right side of the heart cannot accommodate additional venous return. 4. HEPATOMEGALY AND ASCITES: • Hepatomegaly: Liver enlargement from chronic venous congestion. The liver edge is palpable below the right costal margin and may be tender. • Ascites: Accumulation of fluid in the peritoneal cavity, presenting as abdominal distention, fluid wave on percussion, and weight gain. • Right upper quadrant discomfort or fullness from hepatic distention. 5. GASTROINTESTINAL SYMPTOMS: • Anorexia (decreased appetite) from GI tract congestion and elevated hepatic venous pressure. • Nausea and vomiting from GI congestion and hepatic distention. • Abdominal bloating and discomfort. • Constipation from reduced intestinal motility and congestion. • Diarrhea sometimes occurs, paradoxically, from intestinal edema and reduced nutrient absorption. 6. RENAL EFFECTS: • Oliguria: Decreased urine output from reduced renal perfusion (even though venous pressure is high, cardiac output is reduced, and renal perfusion pressure falls). • Nocturia: Mild, especially at night when supine position shifts fluid from interstitial space back into circulation, increasing renal perfusion. 7. HEPATIC DYSFUNCTION: • Elevated liver enzymes (ALT, AST) from hepatic congestion. • Prolonged prothrombin time (PT/INR) from reduced hepatic synthesis of clotting factors. • Hyperbilirubinemia (indirect bilirubin elevated more than direct) from hepatic congestion impairing bilirubin excretion. • These findings are called "congestive hepatopathy." 8. NECK VEIN FINDINGS: • Prominent, distended neck veins (JVD). • Systolic venous pulsations (positive hepatojugular reflex). 9. CARDIAC FINDINGS: • Right ventricular heave (parasternal lift): A palpable impulse at the left lower sternal border (4th-5th intercostal space) indicating RV hypertrophy and dilation. • Tricuspid regurgitation murmur: Systolic murmur heard best at the left lower sternal border that increases with inspiration (Carvallo's sign). • Pulmonary hypertension: Loud P2 (pulmonary component of S2) from closure of the pulmonary valve against high afterload. • S3 galop: Can also occur in RV failure (right-sided S3). 10. SYSTEMIC SYMPTOMS: • Fatigue and weakness from reduced cardiac output. • Cool extremities and poor peripheral perfusion (if cardiac output is severely reduced). NURSING ASSESSMENT OF RIGHT-SIDED HF: SYSTEMIC VENOUS AND FLUID STATUS ASSESSMENT: • Inspect neck veins: Position the patient at 45 degrees; look for distention of the internal jugular vein. Measure JVP by identifying the highest point of venous pulsation above the sternal angle of Louis; normal is <4 cm. Document the angle of bed elevation. • Hepatojugular reflex: Apply gentle, sustained pressure over the liver for 15-30 seconds while observing JVP; rise of >4 cm indicates positive hepatojugular reflex (congestion). • Palpate the liver: Place your hand below the right costal margin and ask the patient to inhale deeply. A normal liver edge is not palpable; a congested liver is enlarged, tender, and may have a pulsatile quality (from tricuspid regurgitation). • Assess for ascites: Observe abdominal distention, test for fluid wave (place one hand on one flank, percuss the other flank; fluid wave will be transmitted), and shift dullness (percussion note changes from dull to resonant when the patient rolls). • Assess for edema: Bilaterally inspect and palpate ankles, feet, lower legs, sacrum (if bedridden), and genitals. Grade edema on a 0-4+ scale (0 = none, 1+ = slight pitting, 2+ = moderate pitting, 3+ = deep pitting, 4+ = very deep pitting with slow return). Note the distribution and progression. CARDIOVASCULAR ASSESSMENT: • Apical pulse: Rate and rhythm. • Blood pressure: Often normal or low in RSHF (unlike LSHF which may have hypertension). • Right ventricular heave: Palpate the left sternal border at the 4th-5th intercostal space; a sustained lift indicates RV hypertrophy. • Auscultate for murmurs: Tricuspid regurgitation murmur (systolic, left lower sternal border, increases with inspiration). • P2 loudness: Compare P2 to A2; a loud P2 indicates pulmonary hypertension. FLUID, WEIGHT, AND INTAKE/OUTPUT ASSESSMENT: • Daily weight: Same method as for LSHF. Edema-associated weight gain indicates fluid retention. • Intake and output: Measure and record; note whether output is adequate relative to intake. • Fluid restrictions: Assess adherence (usually 1.5-2 L/day in HF). RENAL AND HEPATIC FUNCTION: • Monitor urine output: Oliguria may develop in severe cases. • Palpate abdomen for tenderness and distention. • Monitor for signs of hepatic dysfunction (jaundice, dark urine, pale stools). GASTROINTESTINAL STATUS: • Assess for anorexia, nausea, vomiting. • Check bowel sounds and regularity. • Inquire about abdominal discomfort. ACTIVITY AND FUNCTIONAL STATUS: • Use NYHA classification (same as for LSHF). • Document ability to perform ADLs and participate in self-care.

Acute pulmonary edema is a life-threatening emergency in which fluid rapidly accumulates in the pulmonary interstitium and alveoli, severely impairing gas exchange. While pulmonary edema can result from non-cardiac causes (aspiration, sepsis, transfusion, high altitude, near-drowning, pulmonary embolism), the most common cause is acute decompensated left-sided heart failure. An acute event—such as acute MI, sudden increase in blood pressure, acute valvular disease (endocarditis, papillary muscle rupture), or non-adherence to HF medications—suddenly increases LV afterload or decreases contractility, causing acute pulmonary venous pressure to rise precipitously above the plasma oncotic pressure. Fluid floods from the capillaries into the alveoli in a matter of hours. CLINICAL PRESENTATION OF ACUTE PULMONARY EDEMA: The patient typically experiences sudden onset of severe dyspnea, often at night or early morning. Classic findings include: • SEVERE DYSPNEA AT REST: Often sudden onset; patient is in acute distress. • ORTHOPNEA: Severe; patient cannot lie down and sits upright or stands. • ANXIETY AND PANIC: The sensation of drowning generates intense fear; sympathetic activation increases further. • TACHYPNEA: Respiratory rate often >30 breaths/min, sometimes >40. • TACHYCARDIA: Heart rate often >120 bpm from sympathetic activation. • HYPERTENSION: Blood pressure usually elevated (from sympathetic surge and increased afterload), though it may be low if cardiogenic shock develops. • PALLOR AND DIAPHORESIS: Pale, clammy skin from sympathetic activation and poor perfusion. • PINK FROTHY SPUTUM: A pathognomonic sign of severe pulmonary edema. The patient coughs up frothy, pink-tinged sputum that may foam from the mouth. The pink color indicates fluid mixed with red blood cells from alveolar capillaries. • CRACKLES: Bilateral crackles throughout all lung fields (not just bases as in chronic HF). • WHEEZING: Sometimes heard (cardiac asthma). • HYPOXEMIA: SpO2 may be critically low (70-80% on room air) despite rapid breathing. • ALTERED MENTAL STATUS: In severe cases, hypoxemia causes confusion, agitation, or letharness. PATHOPHYSIOLOGY OF ACUTE PULMONARY EDEMA: When pulmonary capillary wedge pressure (PCWP) exceeds approximately 18 mmHg, fluid begins to leak into the interstitium (interstitial edema). When PCWP exceeds 25-30 mmHg, alveolar flooding occurs rapidly. The fluid accumulation is so severe and rapid that the alveolar-capillary barrier is overwhelmed, and blood is literally pushed into the alveoli (alveolar edema). This explains the pink, frothy, blood-tinged sputum: it is pulmonary edema fluid mixed with blood and air, creating froth. VENTILATION-PERFUSION (V/Q) MISMATCH: As alveoli fill with fluid, they are perfused (blood flows through pulmonary capillaries) but not ventilated (air cannot reach the fluid-filled alveoli). This creates a V/Q mismatch and severe hypoxemia that does not respond well to supplemental oxygen alone. The right-to-left shunt (blood passing through non-ventilated alveoli) can be 20-30% or higher. RESPIRATORY MECHANICS: • Pulmonary compliance (stretchiness) is markedly reduced by the edema fluid. • The work of breathing increases dramatically. • Respiratory muscle fatigue develops quickly. • Respiratory failure and the need for intubation/mechanical ventilation can develop within hours if the acute edema is not promptly treated. PRIORITY NURSING INTERVENTIONS FOR ACUTE PULMONARY EDEMA: Remember the mnemonic "LMNOP" (or variations): 1. POSITIONING (Highest Priority to Improve Oxygenation): • Place the patient in HIGH FOWLER'S POSITION (sitting upright, head of bed elevated 90 degrees). • Allow the patient to sit on the side of the bed with legs dangling or standing, if tolerated, to promote venous pooling in the lower extremities and reduce venous return to the heart. • This positioning immediately: - Improves lung expansion and ventilation - Reduces venous return (preload) to the failing heart - Reduces pulmonary capillary pressure and edema formation - Eases the sensation of breathlessness • Do not lay the patient flat; orthopnea will worsen immediately. 2. OXYGENATION (Second Priority): • Apply supplemental oxygen immediately to increase PaO2 and reduce the work of breathing. • Start with nasal cannula at 4-6 L/min or non-rebreather mask at 8-10 L/min to achieve SpO2 ≥90% (target 94-98%, but in COPD with CO2 retention, target 88-92%). • Prepare for non-invasive positive pressure ventilation (NIPPV): - CPAP (continuous positive airway pressure): Delivers positive pressure throughout the respiratory cycle. Improves oxygenation by recruiting closed alveoli and pushing fluid out of the alveoli back into the capillaries. Very effective for acute pulmonary edema. - BiPAP (bilevel positive airway pressure): If the patient cannot tolerate CPAP or if CO2 is elevated. • Prepare for intubation and mechanical ventilation if respiratory failure develops (RR >40, decreasing consciousness, extreme fatigue, SpO2 <85% despite maximal support). • Monitor ABG or VBG: Watch for hypoxemia (PaO2 <60 mmHg), hypercapnia (PaCO2 >45 mmHg indicating CO2 retention), and acidosis. 3. MORPHINE (Third Priority for Hemodynamic Stabilization): • Administer IV morphine 2-4 mg every 15 minutes until symptoms improve or signs of morphine toxicity appear (respiratory depression, hypotension). • Morphine works through multiple mechanisms: - VENODILATION: Reduces preload (venous return) to the heart, decreasing PCWP and pulmonary edema formation. - ANXIOLYSIS: Reduces the intense fear and anxiety, which decreases sympathetic surge and work of breathing. - REDUCED WORK OF BREATHING: Decreases oxygen consumption by the respiratory muscles. - PERIPHERAL VASODILATION: Reduces afterload slightly. • Monitor respiratory rate, blood pressure, and mental status during morphine administration. • Have naloxone (Narcan) available as an antidote if respiratory depression occurs. • Contraindicated in acute right ventricular infarction (where preload reduction is harmful). 4. LOOP DIURETICS (Fourth Priority for Fluid Removal): • Administer IV furosemide (Lasix) in high doses: typical starting dose is 40-80 mg IV push, though doses up to 200-400 mg may be needed in refractory cases or patients on chronic furosemide. • Furosemide works by: - INHIBITING SODIUM REABSORPTION in the thick ascending limb of the loop of Henle, preventing osmotic water reabsorption - INCREASING URINE OUTPUT: The kidneys excrete excess fluid, reducing circulating volume and preload - REDUCING VENOUS RETURN to the heart - DECREASING PULMONARY CAPILLARY PRESSURE • Administer slowly (over 1-2 minutes) for IV push to reduce ototoxicity risk (high-dose, rapid furosemide can cause reversible hearing loss). • Monitor urine output: Urine production should increase significantly within 30-60 minutes (often 100+ mL/hour in the first 1-2 hours). • Monitor serum electrolytes, especially potassium, as loop diuretics cause significant potassium wasting. • Assess for dehydration once the acute edema resolves; do not over-diurese, or the patient may develop hypotension and acute kidney injury. 5. NITRATES/VASODILATORS (Fourth Priority, Often Given With Diuretics): • Administer IV nitroglycerin (nitrate vasodilator) or hydralazine to reduce both preload and afterload. • IV nitroglycerin: Start at 5-10 mcg/min and titrate up by 5-10 mcg/min every 5-10 minutes until symptoms improve or systolic BP drops to 90-100 mmHg. Works through: - VENODILATION: Reduces preload - ARTERIOLAR DILATION: Reduces afterload - REDUCED MYOCARDIAL OXYGEN DEMAND • Hydralazine 10-20 mg IV every 4-6 hours: Primarily an arteriolar dilator; reduces afterload. Often combined with a nitrate. • Hold if systolic BP <90-100 mmHg (risk of cardiogenic shock). • Monitor blood pressure closely; can cause hypotension and reflex tachycardia. • Common side effects: headache (from vasodilation of cerebral vessels), light-headedness. ADDITIONAL SUPPORTIVE MEASURES: • Continuous cardiac monitoring: Watch for dysrhythmias (common with acute MI or severe electrolyte abnormalities). • Continuous pulse oximetry: Document SpO2 trend. • IV access: Establish large-bore peripheral IV or central line for medication administration and monitoring. • Foley catheter: Insert to accurately measure urine output and assess kidney function; strict I&O. • Frequent reassessment: Every 15-30 minutes initially—assess respiratory rate, work of breathing, crackles, SpO2, blood pressure, mental status. As acute edema resolves, crackles should clear from the bases upward. • Identify and treat the precipitating cause: Acute MI, uncontrolled hypertension, arrhythmia, medication non-adherence, acute valvular regurgitation, infection, thyroid storm, etc. • NPO status initially: Then soft diet as symptoms improve. • Emotional support: Patient and family are frightened; reassure, explain procedures, and keep them informed of the plan. COMMON MISTAKES TO AVOID: • Laying the patient flat or semi-recumbent: This increases pulmonary edema immediately; always maintain high Fowler's. • Under-treating with morphine or diuretics from fear of respiratory depression or renal failure: In acute pulmonary edema, under-treatment is more dangerous than over-treatment; respiratory failure from untreated edema is the real threat. • Forgetting to address the underlying cause: Simply removing fluid without treating the MI, controlling the blood pressure, or treating the arrhythmia will result in re-accumulation of edema. • Excessive oral or IV fluid intake: Keep fluid intake restricted (typically 1.5 L/day in HF); avoid D5W, which is hypotonic and worsens edema. • Not preparing for intubation: If the patient's respiratory status worsens despite maximal medical management, be ready to intubate; do not wait until the patient is in extremis. PROGNOSIS AND RECOVERY: With prompt, aggressive treatment, most patients with acute pulmonary edema improve rapidly over 4-24 hours. Crackles clear from the bases upward. Urine output increases dramatically. Dyspnea improves, and the patient becomes calmer. However, mortality is high if treatment is delayed or if the underlying cause (e.g., acute MI with cardiogenic shock) is severe. After the acute episode resolves, the focus shifts to identifying the precipitating cause, optimizing chronic HF medications, and preventing recurrence through patient education and close follow-up.

Accurate diagnosis of heart failure requires integration of clinical presentation with objective diagnostic testing. In the Philippine healthcare context, where access to advanced imaging varies by facility type (tertiary centers have echo-labs; rural health units may not), clinical judgment becomes even more critical. BLOOD BIOMARKERS: 1. B-TYPE NATRIURETIC PEPTIDE (BNP) AND N-TERMINAL PRO-BNP (NT-proBNP): • BNP and NT-proBNP are peptides released by cardiac ventricles in response to volume expansion and ventricular wall stress. • BNP diagnostic cutoff: >100 pg/mL suggests possible HF; >400-500 pg/mL indicates likely HF; >900 pg/mL indicates HF with high probability. • NT-proBNP diagnostic cutoff: >125 pg/mL (or >900 pg/mL in acute decompensated HF settings) suggests HF. • Higher levels correlate with severity of HF and worse prognosis. • ADVANTAGES: Highly sensitive for HF; useful for excluding HF in acute dyspnea (high negative predictive value). Levels trend downward with HF treatment and correlate with response to therapy. • LIMITATIONS: Elevated in renal failure (NT-proBNP more than BNP) even without HF; elevated in sepsis, pulmonary embolism, acute coronary syndrome; elevated in advanced age without HF. Not specific for HF. • Clinical pearl for NLE: In a dyspneic patient, if BNP is normal and NT-proBNP is normal, HF is unlikely. If both are elevated, HF is likely, but other causes must be ruled out. 2. TROPONIN: • Cardiac troponin I (cTnI) or troponin T (cTnT): Highly sensitive and specific for myocardial injury/necrosis. • Elevated in acute coronary syndrome, myocarditis, heart failure (especially acute decompensated), sepsis, PE, renal failure, etc. • In HF, troponin elevation usually indicates myocardial injury from supply-demand mismatch or acute ischemia. • Used to risk-stratify HF patients and guide prognosis, not for diagnosis. 3. COMPLETE BLOOD COUNT (CBC): • Hemoglobin and hematocrit: Anemia (Hgb <12 g/dL in women, <13.5 g/dL in men) is common in HF and correlates with worse prognosis. May result from chronic kidney disease, chronic inflammation, or hemodilution (fluid overload). • White blood cell count: Elevated in acute decompensated HF (reflects inflammatory state); infection should be ruled out. 4. BASIC METABOLIC PANEL (BMP) AND ELECTROLYTES: • Sodium: Hyponatremia (Na <130 mEq/L) indicates severe fluid overload (excessive water retention relative to sodium loss); associated with poor prognosis. Often seen in decompensated HF. • Potassium: Hypokalemia increases digoxin toxicity and arrhythmia risk; hyperkalemia (especially with ACEi/ARB use) can cause life-threatening dysrhythmias. Monitor closely with diuretics and RAAS inhibitors. • Creatinine and BUN: Elevated indicates renal dysfunction. Worsening renal function during HF treatment ('cardiorenal syndrome') requires careful fluid and medication management. • Creatinine is used to calculate GFR for medication dosing. • BUN-to-creatinine ratio >20:1 suggests prerenal azotemia (poor renal perfusion from low cardiac output); ratio <10:1 suggests intrinsic renal disease. 5. LIVER FUNCTION TESTS (LFTs): • ALT, AST, bilirubin, and alkaline phosphatase: Elevated in 'congestive hepatopathy' from RSHF (hepatic congestion). A pattern of disproportionate elevation of transaminases relative to bilirubin and alkaline phosphatase is typical. • PT/INR: Prolonged (INR >1.5) indicates impaired hepatic synthesis of clotting factors, seen in advanced congestive hepatopathy. Important for anticoagulation management in AFib. 6. LIPID PANEL: • Total cholesterol, LDL, HDL, triglycerides: Important for assessing cardiovascular risk and guiding lipid-lowering therapy (statins). CARDIAC IMAGING: 1. ELECTROCARDIOGRAM (ECG): • Often abnormal in HF; findings depend on the underlying cause. • LSHF (systolic dysfunction): Often shows: - LV hypertrophy (increased QRS voltage in precordial leads, especially V5-V6) - ST-T wave changes (non-specific) - Q waves (indicating prior MI) - Atrial fibrillation (common arrhythmia in HF) - Poor R wave progression in anterior leads (extensive anterior MI) • RSHF: May show: - RV hypertrophy (prominent R wave in V1, S wave in V5-V6—'right ventricular strain pattern') - Right axis deviation • Findings are NOT specific for HF; the ECG is used to identify precipitating causes (MI, LVH) and complications (AFib, heart blocks). • ECG is essential for ruling out acute MI in patients presenting with dyspnea. 2. CHEST X-RAY (CXR): • Highly useful and widely available in Philippine health centers. • LSHF findings: - Cardiomegaly: Cardiac silhouette width >50% of the thoracic width on PA view (or cardiothoracic ratio >0.5). - Pulmonary vascular congestion: Cephalalization of pulmonary blood flow (upper lobe vessels distended; lower lobe vessels constricted). - Kerley B lines: Horizontal lines at the lung periphery (especially at bases) from interstitial edema; very specific for pulmonary edema. - Alveolar edema: 'Butterfly' or 'bat-wing' pattern of infiltrates radiating from the hilum; indicates severe pulmonary edema. - Pleural effusions: Often bilateral; usually larger on the right; indicates elevated pulmonary capillary pressure. - Pulmonary edema pattern: Starts in the central lung zones (around hilum) and, if severe, spreads peripherally. • RSHF findings: - Cardiomegaly (especially RV enlargement) - Enlarged right atrium (straightening of the right heart border) - Absence of pulmonary edema (if pure RSHF without LSHF) • CXR findings lag behind clinical improvement; crackles may clear before CXR shows complete resolution of pulmonary edema (and vice versa). 3. ECHOCARDIOGRAPHY (ECHO): • The gold standard for HF diagnosis in most guidelines; provides the most definitive assessment. • MEASUREMENTS AND FINDINGS: - Left ventricular ejection fraction (LVEF or EF): The percentage of blood in the LV that is ejected with each contraction. Normal ≥55%. HF classification: • HFrEF: EF ≤40% • HFmrEF: EF 41-49% • HFpEF: EF ≥50% - Left ventricular end-diastolic dimension (LVEDD): Enlarged (>55 mm) in dilated cardiomyopathy and LSHF. - Wall thickness: Normal 8-11 mm; >11 mm indicates LV hypertrophy (from hypertension, aortic stenosis, athletic heart). - Segmental wall motion abnormalities: Specific regions of the LV may be hypokinetic (reduced contraction) or akinetic (no contraction) from prior MI or cardiomyopathy. - E/e' ratio: A marker of diastolic function; elevated ratio (>14) indicates elevated filling pressures and diastolic dysfunction (important in HFpEF). - Left atrial volume: Enlarged LA indicates chronic elevated LV filling pressures. - Valve function: Identifies stenosis or regurgitation; functional mitral or tricuspid regurgitation from annular dilation. - RV function: RV fractional area change or RV longitudinal strain (advanced technique). - Estimated pulmonary artery systolic pressure (from tricuspid regurgitation velocity): Elevated (>35-40 mmHg) indicates pulmonary hypertension. • ADVANTAGES: Non-invasive, no radiation, real-time assessment of structure and function. • LIMITATIONS: Operator-dependent; quality depends on patient body habitus and acoustic windows; contraindicated if patient has defibrillator leads (relative contraindication; some newer devices are echo-compatible). • In the Philippine context: Echocardiography availability varies; tertiary hospitals and many private clinics have echo labs; rural health units typically do not. Telemedicine echo interpretation is emerging in some regions. 4. STRESS TESTING: • Exercise stress test (treadmill or bicycle): Used to assess for inducible ischemia in patients with HF and suspected CAD. Contraindicated in acutely decompensated HF. • Dobutamine stress echo: Simulates exercise with IV dobutamine; useful when patients cannot exercise. Can induce dysrhythmias. • Not first-line for HF diagnosis but useful for assessing ischemic versus non-ischemic etiology and prognosis. 5. CARDIAC CATHETERIZATION AND CORONARY ANGIOGRAPHY: • Invasive procedure; gold standard for assessing coronary artery disease. • Hemodynamic assessment: Measures: - Right atrial pressure (RAP): Normal 2-8 mmHg; elevated in RSHF. - Pulmonary artery pressure (PAP): Normal systolic 20-30 mmHg, diastolic 8-15 mmHg; elevated in pulmonary hypertension. - Pulmonary capillary wedge pressure (PCWP): Reflects LV filling pressure; normal 6-12 mmHg; elevated (>18 mmHg) indicates elevated filling pressures and is associated with pulmonary congestion. PCWP >25-30 mmHg causes pulmonary edema. - Cardiac output (CO): Normal ~4-8 L/min; reduced in HF. - Systemic vascular resistance (SVR): Elevated in HF from compensatory vasoconstriction. • Coronary angiography: Identifies coronary artery disease; determines if revascularization (PCI or CABG) is indicated. • Reserved for patients with HF and angina, positive stress tests, or when CAD etiology is suspected; not done routinely for uncomplicated HF. • Risk-stratifying tool in advanced HF (guides transplantation candidacy). 6. OTHER IMAGING: • Cardiac MRI: High-resolution assessment of myocardial structure and function; can identify scar patterns (e.g., ischemic vs. non-ischemic). Not yet widely available in most Philippine hospitals. • Nuclear imaging (myocardial perfusion imaging or MUGA scan): Assesses wall motion and perfusion; less commonly used now that echo and MRI are available. HEMODYNAMIC PROFILES (From Acute Decompensated HF Classification): Understanding hemodynamic profiles (based on Forrester classification) helps guide treatment: • Warm and Dry (Optimal): Adequate cardiac output (warm extremities), normal PCWP (<18 mmHg). Patient feels well. Goal is to maintain this state. • Warm and Wet: Adequate cardiac output but elevated PCWP (>18 mmHg); patient has pulmonary and/or systemic congestion but adequate perfusion. Needs diuretics and vasodilators. • Cold and Dry: Reduced cardiac output (cool extremities, poor perfusion) but normal PCWP (<18 mmHg). Needs inotropes and fluids cautiously. • Cold and Wet: Reduced cardiac output AND elevated PCWP; patient is in cardiogenic shock. Most ominous profile. Needs inotropes, vasodilators, and possibly mechanical support. CLINICAL ASSESSMENT INTEGRATION: Biomarkers and imaging do not replace clinical judgment. A patient with elevated BNP and echo showing HFrEF but no signs or symptoms of congestion (orthopnea, crackles, JVD, edema) does not need aggressive diuresis. Similarly, a patient with clinical signs of HF and a mildly elevated BNP may still have HF, particularly if the test was drawn late in the acute event. The art of nursing is integrating objective findings with clinical presentation, patient response to treatment, and hemodynamic profile to guide care.

A cardiac dysrhythmia (or arrhythmia) is any abnormality in the rate, rhythm, or conduction of the heartbeat. Dysrhythmias can be benign, symptomatic but stable, or immediately life-threatening depending on the rate, regularity, duration, and underlying ventricular function. As a BSN graduate preparing for the NLE, you must assess dysrhythmias not only by their ECG appearance but by their hemodynamic consequences. A rhythm is clinically important only if it compromises cardiac output, tissue perfusion, or is associated with a high risk of deterioration into a lethal rhythm. CLINICAL ASSESSMENT OF DYSRHYTHMIAS: Always follow the systematic ABCs: 1. Is the patient ALERT and RESPONSIVE? (Consciousness) 2. What is the BLOOD PRESSURE? 3. Is the patient COMPLAINING of symptoms (chest pain, dyspnea, dizziness, syncope, palpitations)? A patient with a rapid ventricular tachycardia who is hypotensive and unconscious requires immediate cardioversion (emergency). A patient with the same rhythm who is alert, normotensive, and asymptomatic may be managed more conservatively with IV antiarrhythmics. This principle guides the acuity of intervention. KEY DYSRHYTHMIA CLASSIFICATIONS: 1. SINUS DYSRHYTHMIAS: These originate from the sinoatrial (SA) node and maintain normal AV conduction (P wave before each QRS); they are usually benign but may indicate underlying pathology. • Sinus bradycardia: Heart rate <60 bpm, regular rhythm, normal PR and QRS intervals. Causes: athletic training, vagal stimulation (Valsalva, carotid massage), hypoxemia, hypothermia, medications (beta-blockers, calcium channel blockers, digoxin, amiodarone), increased intracranial pressure, myocardial infarction (especially inferior MI with RV involvement). Treat only if SYMPTOMATIC (dizziness, syncope, hypotension, chest pain) with: - IV atropine 0.5 mg, may repeat every 3-5 minutes (max 3 mg total). Atropine blocks vagal acetylcholine at the AV node, increasing AV conduction velocity and heart rate. - Transcutaneous or transvenous pacemaker if atropine ineffective or if the patient is acutely unstable. - Do NOT treat asymptomatic bradycardia; athlete's heart with HR 40-50 is normal and requires no treatment. • Sinus tachycardia: Heart rate >100 bpm (in adults; >130 in infants), regular rhythm, normal P-QRS-T morphology. Treat the underlying CAUSE, not the rhythm itself: - Pain: Administer analgesics - Fever: Give antipyretics, fluids, and antibiotics if infection - Hypovolemia: Administer IV fluids - Anxiety: Reassure patient, consider anxiolytics - Thyroid storm: Beta-blockers and antithyroid drugs - Hypoxemia: Supplement oxygen - Anemia: Transfuse if needed - Sepsis: Initiate sepsis protocol • Sinus tachycardia is the body's appropriate response to a physiologic demand; suppressing it without treating the cause does more harm than good. 2. ATRIAL DYSRHYTHMIAS: These originate above the ventricles (atria or AV node) and generally have narrow QRS complexes (<0.12 seconds) because conduction through the ventricles is normal. • Atrial flutter: Rapid, regular atrial activity at 250-350 bpm (often appearing as a 'sawtooth' or 'flutter wave' pattern on ECG, especially visible in leads II, III, aVF). The ventricular response is typically regular and often at a rate of 150 bpm (2:1 conduction; every other atrial beat is conducted through the AV node). If the AV node conducts each atrial impulse (1:1 conduction), ventricular rate can be 250+ bpm—a hemodynamic emergency. - Treatment depends on hemodynamic stability: • Stable (alert, normotensive, asymptomatic or minimally symptomatic): Rate control with beta-blockers (metoprolol 25-50 mg PO daily), calcium channel blockers (diltiazem 30 mg PO TID), or digoxin. Antiarrhythmic drugs (flecainide, propafenone, sotalol, amiodarone) may convert rhythm. Anticoagulation as per AFib guidelines. • Unstable (hypotension, altered consciousness, severe dyspnea, chest pain): Synchronized cardioversion at 50-100 J (biphasic defibrillator) after IV sedation and analgesia. - Risk of thrombus formation in the atrial appendage is lower than AFib but still present; anticoagulation is recommended for flutter ≥48 hours duration. • Atrial fibrillation (AFib): The most common chronic dysrhythmia in the general population and especially in elderly and HF patients. Pathophysiology: Multiple ectopic foci in the atria fire chaotically and irregularly, causing disorganized atrial contraction and irregular ventricular responses. The atrial rate is typically 400-600 bpm (too fast to count), creating a chaotic baseline with no discernible P waves. - ECG characteristics: • No discernible P waves (baseline appears wavy or chaotic) • Irregularly irregular ventricular response (RR intervals vary unpredictably) • QRS complexes are typically normal width (<0.12 seconds) unless there is underlying conduction abnormality or aberrant conduction • The 'irregularly irregular' rhythm is pathognomonic (diagnostic) for AFib - Hemodynamic consequences: • Loss of atrial kick (atria no longer contract effectively): In normal sinus rhythm, the atrial contraction contributes 15-25% of ventricular filling ('atrial kick'). In AFib, this is lost, reducing stroke volume by 10-20%. • Blood stasis in the atrium: Chaotic atrial contraction causes blood to pool, especially in the left atrial appendage, forming clots. These clots can embolize to the cerebral circulation, causing stroke. AFib increases stroke risk 4-5 fold compared to normal sinus rhythm. - Clinical presentation depends on ventricular rate and underlying cardiac function: • Fast AFib (rate >120): Palpitations, dyspnea, chest pain, dizziness, syncope if rate is very rapid or patient has poor ventricular function • Slow AFib (rate <60): Often asymptomatic or minimally symptomatic • AFib in a patient with normal EF: Often tolerated well; symptoms may be minimal • AFib in a patient with HFrEF: Often not tolerated; rapid rate increases oxygen demand; loss of atrial kick reduces stroke volume in an already-failing ventricle; can precipitate acute decompensation and pulmonary edema - Management of AFib: • Anticoagulation (MOST IMPORTANT): All patients with AFib and CHA2DS2-VASc score ≥1 require anticoagulation to prevent embolic stroke: - Warfarin (target INR 2-3): Traditional agent; requires frequent INR monitoring; interacts with many drugs and foods (vitamin K intake) - Direct oral anticoagulants (DOACs): Apixaban (Eliquat), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Lixiana). Non-warfarin alternatives; fixed dose; no monitoring required; less dietary interaction; contraindicated in severe renal disease (except apixaban for some agents). DOACs are increasingly preferred in new-onset AFib because of convenience and non-inferiority to warfarin in trials. - Aspirin alone is NOT recommended for stroke prevention in AFib (inadequate protection) • Rate control: Keep resting ventricular rate 60-100 bpm (or <110 bpm in some guidelines, 'lenient rate control'): - Beta-blockers (metoprolol, atenolol, carvedilol): First-line for most patients - Calcium channel blockers (diltiazem, verapamil): If beta-blockers contraindicated - Digoxin: Useful in HF with AFib (both treats HF via positive inotrope and controls AFib via AV node blockade); less effective in high-adrenergic states (exercise, acute illness) • Rhythm control (convert to and maintain sinus rhythm): Reserved for symptomatic patients or those who do not tolerate AFib: - Amiodarone IV: Most effective antiarrhythmic for AFib, especially in acute settings - Flecainide, propafenone: Effective but contraindicated in structural heart disease (MI, HF, LVH) due to proarrhythmic risk - Sotalol: Beta-blocker + antiarrhythmic; for selected patients - Synchronized cardioversion: If hemodynamically unstable - Management guidelines (AFFIB specific): • Acute AFib <48 hours: May attempt rate control or rhythm control; anticoagulation not acutely necessary if <48 hours, but if unsure of duration, anticoagulate • Chronic AFib or AFib >48 hours: Rate control strategy is non-inferior to rhythm control for most patients. Anticoagulation is essential. • Anticoagulation duration: Lifelong if AFib persists or if multiple AFib recurrences; can be stopped after cardioversion if it was a single episode provoked by an acute illness (post-op AFib, AFib in setting of acute MI that was revascularized, AFib in hyperthyroidism that was treated) 3. ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA (AVNRT): A common type of supraventricular tachycardia (SVT) that occurs due to dual pathways within the AV node. The rhythm is regular at 150-250 bpm. If hemodynamically stable, treat with IV adenosine 6 mg rapid push followed by saline flush; if unsuccessful, repeat with 12 mg. Adenosine blocks AV node conduction, terminating the reentry circuit. If adenosine is ineffective or contraindicated, use beta-blockers, calcium channel blockers, or synchronized cardioversion if unstable. 4. VENTRICULAR DYSRHYTHMIAS: These originate below the AV node (in the ventricles) and typically have wide QRS complexes (≥0.12 seconds). They are more dangerous than atrial dysrhythmias because: • Ventricular dysrhythmias indicate cardiac irritability or severe structural disease • Many ventricular dysrhythmias can degenerate into ventricular fibrillation (cardiac arrest) • They compromise cardiac output more severely than atrial dysrhythmias • Premature ventricular contractions (PVCs): Early beats arising from a ventricular focus. Characteristics: - Wide QRS (≥0.12 seconds) - No preceding P wave - T wave typically opposite in polarity to the QRS (ST segment and T wave on opposite side of baseline) - Compensatory pause: The interval between the beat before the PVC and the beat after the PVC equals exactly two normal intervals (full compensatory pause); this distinguishes PVCs from PACs - Often described by location: unifocal (same appearance) vs. multifocal (different appearances), suggesting different ectopic sites - Frequency patterns: Occasional (1-2 per minute), frequent (>5-10 per minute), coupled (two consecutive PVCs), triplet (three consecutive PVCs), bigeminy (alternating normal beat and PVC), trigeminy (normal, normal, PVC pattern) - Triggers: Caffeine, hypoxemia, hypokalemia, hypomagnesemia, sympathetic stimulation, digitalis toxicity, myocardial ischemia/infarction, myocarditis, cardiomyopathy - Treatment depends on symptoms and underlying disease: • Asymptomatic, rare PVCs in structurally normal heart: NO treatment; reassure patient. Patient may perceive PVCs as 'palpitations' or 'skipped beats'; explanation and reassurance often alleviates anxiety. • Symptomatic or frequent PVCs (>10-20/min): Treat underlying causes (correct electrolytes, cease caffeine, treat ischemia). If persistent, beta-blockers or calcium channel blockers may reduce frequency. • PVCs in setting of myocardial infarction or poorly tolerated: IV lidocaine or amiodarone. Historically, prophylactic lidocaine was given to post-MI patients, but evidence shows it does NOT improve survival and increases proarrhythmic risk; so it is no longer routinely used unless PVCs are triggering runs of VT. • Ventricular tachycardia (VT): Three or more consecutive PVCs at a rate >100 bpm. Characteristics: - Wide QRS complexes (≥0.12 seconds), usually >0.14 seconds - Rate typically 100-250 bpm - Regular or slightly irregular rhythm - AV dissociation (P waves march through, independent of QRS complexes) or fusion beats (hybrid beats showing characteristics of both conducted and ectopic impulses) are diagnostic but not always present - Duration classified as: • Monomorphic VT: All QRS complexes identical in shape; suggests a single ectopic focus or reentry circuit • Polymorphic VT: QRS complexes vary in shape and axis; suggests multiple foci or changing ectopic site. Torsades de pointes is a special type of polymorphic VT that twists around the baseline; often associated with prolonged QT interval and electrolyte abnormalities - Duration and hemodynamic effect: • Sustained VT: Lasts >30 seconds or requires termination due to hemodynamic compromise • Non-sustained VT: Spontaneously terminates within 30 seconds - Etiology: Often associated with significant structural heart disease (MI with scar, cardiomyopathy, HF); can occur in electrolyte abnormalities, drug toxicity (digoxin, antiarrhythmics), myocarditis, or rarely in structurally normal hearts (idiopathic VT) - Hemodynamic consequences depend on rate and underlying ventricular function: • VT with pulse but hemodynamically stable (alert, normotensive, asymptomatic): Treat with IV amiodarone (150 mg infused over 10 minutes, then 1 mg/min infusion) or procainamide/other antiarrhythmics • VT with pulse but hemodynamically unstable (hypotensive, altered consciousness, severe dyspnea, chest pain): Synchronized cardioversion at 100 J (biphasic defibrillator). Sedate with IV midazolam or propofol and analgesia (morphine, fentanyl) before cardioversion if conscious. • Pulseless VT: See below • Ventricular fibrillation (VF): Chaotic, disorganized ventricular electrical activity with no organized contraction. The ECG shows a 'bag of worms' or chaotic baseline with no discernible QRS complexes. NO cardiac output; patient is in cardiac arrest (unresponsive, pulseless, apneic). VF is a 'shockable' rhythm. - Hemodynamic consequence: NO cardiac output; immediate irreversible brain and organ damage within minutes - Treatment: IMMEDIATE unsynchronized defibrillation at 200 J (biphasic) or 360 J (monophasic); followed by CPR (chest compressions 100-120 bpm) and IV epinephrine 1 mg every 3-5 minutes. Do NOT delay defibrillation to start IVs or medications; defibrillation is the only therapy that can restore an organized rhythm in VF. Defibrillation success rate decreases with each minute of delay; survival is nearly zero if VF is witnessed and defibrillation delayed >20 minutes. - Prognosis: If VF is witnessed and defibrillated promptly (within 3-5 minutes), survival rates are 40-60%; if delayed >30 minutes, survival is <5% - Prevention: Automated external defibrillators (AEDs) in public places, early recognition, early CPR, and early defibrillation (the 'Chain of Survival') • Pulseless electrical activity (PEA): Organized ECG rhythm (could be normal sinus, bradycardia, VT, or any other rhythm) but NO palpable pulse and NO cardiac output. Essentially, the electrical system is firing but the mechanical system (contraction) is not. Outcomes are very poor; causes must be identified and reversed: - Causes (remember 'Hs and Ts'): • Hypovolemia (hemorrhage, dehydration, sepsis) • Hypoxemia (respiratory failure, airway obstruction, severe pulmonary edema) • Hypothermia (severe cold) • Hydrogen ion (severe acidosis) • Hyperkalemia or hypokalemia (extreme electrolyte abnormalities) • Tension pneumothorax (collapsed lung compressing the heart) • Tamponade (pericardial fluid compressing the heart) • Thrombosis (massive PE, acute MI with cardiogenic shock) • Toxins (drug toxicity, poisoning) - Treatment: CPR + IV epinephrine + identify and treat the underlying cause. Epinephrine does NOT restore organized rhythm; CPR and treating the cause are the only things that work. • Asystole ('flatline'): Complete absence of electrical activity on the monitor; ECG is a straight line. Patient is in cardiac arrest. Asystole has an extremely poor prognosis; it typically represents end-stage disease or severe global myocardial injury. - Not a 'shockable' rhythm: Defibrillation will not help; CPR and epinephrine are the treatments - Treatment: High-quality CPR, IV epinephrine 1 mg every 3-5 minutes, IV atropine 1 mg every 3-5 minutes (though evidence for atropine in asystole is weak) - Prognosis: Survival from out-of-hospital asystole is nearly zero unless there is a reversible cause (severe hypothermia, drug toxicity) or it develops during in-hospital resuscitation (where there is immediate access to advanced interventions) IMPORTANT CLINICAL PEARL ON CARDIAC ARREST RHYTHMS: During CPR, the two 'shockable' rhythms are VF and pulseless VT. The two 'non-shockable' rhythms are asystole and PEA. The FIRST action for VF or pulseless VT is DEFIBRILLATION; for asystole and PEA, the FIRST action is HIGH-QUALITY CPR (hard and fast, 100-120 compressions per minute, allowing full recoil, minimizing interruptions). Medications (epinephrine, amiodarone) are given during CPR; they do NOT replace chest compressions.

A pacemaker is an electrical device that delivers electrical impulses to stimulate myocardial contraction when the heart's intrinsic conduction system fails or is inadequate. Pacemakers compensate for bradycardia, heart blocks, and asystole, allowing patients who would otherwise require continuous monitoring in ICU to live independently. Understanding pacemaker function, recognizing pacemaker malfunction, and teaching patients proper management are critical NLE concepts. INDICATIONS FOR PACEMAKER PLACEMENT: 1. SYMPTOMATIC BRADYCARDIA: • Sinus bradycardia with symptoms (dizziness, syncope, hypotension, reduced exercise capacity) not responding to atropine • Sick sinus syndrome: Alternating periods of sinus bradycardia and tachyarrhythmias; inappropriate sinus response to exercise 2. HEART BLOCKS: • Second-degree block type II (Mobitz II): Intermittent failure of AV node conduction; high risk of progression to complete heart block • Third-degree AV block (complete heart block): Complete dissociation between atrial and ventricular rhythms; no atrial impulses are conducted to the ventricles. Ventricular rate is slow (30-60 bpm) and maintained by escape rhythm from below the AV node (bundle of His or ventricular focus). 3. ASYSTOLE: • Absence of any cardiac electrical activity; pacemaker can initiate rhythm if the myocardium is still viable 4. HYPERTROPHIC CARDIOMYOPATHY: • Some patients with HCM benefit from dual-chamber pacing, which synchronizes atrial and ventricular contraction 5. SLEEP APNEA: • Emerging indication for pacing in some patients with severe obstructive sleep apnea TYPES OF PACEMAKERS: 1. TEMPORARY PACEMAKERS: Used for acute, short-term pacing needs (hours to days): • Transcutaneous pacemaker (external pacemaker): - Two adhesive pacing pads placed on the patient's chest (negative pad on the left anterior chest, positive pad on the left midaxillary line, 4th-5th intercostal space) - Connected to an external pacemaker box - Non-invasive and rapidly deployable in emergencies (asystole, severe bradycardia with hemodynamic compromise) - Uncomfortable for conscious patients (electrical stimulation causes pain); sedation/analgesia required - Temporary measure until transvenous pacemaker can be placed or intrinsic rhythm recovers - Does NOT require an operating room or specialized procedure room - Used in the Philippines in EDs and ambulances for stabilization during transport • Transvenous pacemaker: - Pacing catheter (wire with an electrode tip) threaded through a central vein (usually right internal jugular vein or subclavian vein) into the right atrium and/or right ventricle - The catheter is connected to an external pacemaker box worn on a belt or stand beside the bed - More reliable than transcutaneous; allows for weeks of pacing if needed - Requires proper placement (confirmed by CXR or fluoroscopy) and careful maintenance - Risk of infection, catheter migration, or perforation of the RV - Used while awaiting placement of a permanent pacemaker or for temporary pacing after MI or cardiac surgery - Requires sterile technique and usually is placed by a cardiologist or intensivist in the ICU or catheterization lab 2. PERMANENT PACEMAKERS: Surgically implanted subcutaneously, usually below the left clavicle: • Single-chamber pacemaker: - Paces either the atrium (atrial pacing) or the ventricle (ventricular pacing), but not both - Simpler technology; lower cost; fewer wires - Used in patients with AF (where atrial pacing is not beneficial) or in those who do not need dual-chamber sensing - Slightly less physiologic than dual-chamber pacing • Dual-chamber pacemaker: - Two leads: one in the right atrium and one in the right ventricle - Allows AV synchronization: The pacemaker senses atrial activity and, after a programmable delay (AV delay), paces the ventricle if needed - More physiologic: Preserves atrial kick, maintains AV synchronization, allows rate adaptation to exercise - Used in patients with normal sinus function who need ventricular pacing (e.g., second-degree type II or third-degree block) - More expensive; requires two lead placements and more complex programming • Biventricular pacemaker (cardiac resynchronization therapy, CRT): - Three leads: one in the right atrium, one in the right ventricle, and one in the coronary sinus (left ventricle) via the coronary sinus vein - Designed for patients with HFrEF and wide QRS complexes (≥120 ms), indicating electrical dyssynchrony (left ventricle contracts late relative to the right ventricle) - CRT paces both ventricles simultaneously or with optimized timing to restore mechanical synchrony - Improves LV contractility, reduces mitral regurgitation, and improves exercise tolerance and survival in selected HF patients - Often combined with an implantable cardioverter-defibrillator (CRT-D) in HFrEF patients at risk of sudden cardiac death • Implantable cardioverter-defibrillator (ICD): - Similar to a pacemaker but with the additional capability of delivering high-energy shocks (defibrillation) to terminate VF or pulseless VT - Used in patients at high risk of sudden cardiac death from VF/VT (post-MI with reduced EF, non-ischemic cardiomyopathy with EF ≤35%, inherited channelopathies like long QT or Brugada syndrome, post-cardiac arrest survivors) - Can also function as a pacemaker for bradycardia - Antitachycardia pacing (ATP): Some ICDs can deliver rapid pacing bursts to try to pace-terminate VT before resorting to shock (less painful if it works) - Shock is very painful; patients describe it as a 'kick' or 'punch' in the chest; can be emotionally traumatic but life-saving PACEMAKER NOMENCLATURE (NBD Code): Pacemakers are classified by the NBD code (now extended to NBDI code): • FIRST LETTER (Chamber Paced): A (atrium), V (ventricle), D (dual—both atrium and ventricle), O (none) • SECOND LETTER (Chamber Sensed): A (atrium), V (ventricle), D (dual), O (none) • THIRD LETTER (Response to Sensing): I (inhibited), T (triggered), D (dual—inhibited and triggered), O (none) Examples: • AAI: Atrial pacing, atrial sensing, inhibited response. If the atrium senses an intrinsic P wave, the pacemaker is inhibited and does not pace. Used for sinus node disease with intact AV conduction. • VVI: Ventricular pacing, ventricular sensing, inhibited response. If the ventricle senses an intrinsic QRS, pacing is inhibited. Used for AF with slow ventricular rate. • DDD: Dual-chamber pacing, dual-chamber sensing, dual response (inhibited and triggered). Physiologic pacing; the gold standard for most indications. • VOO: Ventricular pacing, no sensing, no response (asynchronous pacing). Used in patients with no intrinsic rhythm (complete asystole); the pacemaker fires at a fixed rate regardless of any intrinsic activity. Risk of competitive pacing (pacemaker spike landing on a T wave, triggering VF) if even occasional intrinsic beats are present. PACEMAKER FUNCTION AND COMPONENTS: 1. THE PULSE GENERATOR (Battery and Circuitry): • Located in the subcutaneous pocket below the clavicle • Battery: Typically lithium-iodine; lasts 7-15 years depending on use and current drain • Circuitry: Sensing circuit (detects intrinsic cardiac activity), pacing circuit (generates electrical impulses), and logic circuits (process information and make pacing decisions) 2. THE LEADS: • Insulated wires connecting the pulse generator to the myocardium • Tip electrode: Delivers electrical impulse (cathode); positioned on the endocardium of the right atrium and/or right ventricle • Return electrode: Can be the proximal coil on the lead (unipolar) or a ring electrode on the lead (bipolar) • Bipolar lead configuration is more specific for sensing intrinsic activity and less prone to sensing muscle artifact or external interference 3. KEY PROGRAMMABLE PARAMETERS: • PACING RATE (Lower Rate Limit, LRL): The rate at which the pacemaker will pace if no intrinsic activity is sensed. Usually set to 60 bpm (may be 50-80 bpm depending on patient's needs). In VVI pacing, if the patient's intrinsic rate is less than the LRL, the pacemaker paces at the programmed rate. • UPPER RATE LIMIT (URL): The fastest rate at which the pacemaker will follow intrinsic atrial activity (in dual-chamber pacing). Prevents the pacemaker from tracking fast atrial activity (e.g., AFib) and pacing the ventricle at an inappropriately fast rate. • SENSITIVITY: How sensitive the pacemaker is to intrinsic cardiac activity. If too sensitive, the pacemaker may sense muscle artifact or external electrical noise (oversensing). If not sensitive enough, it may miss intrinsic beats (undersensing). Sensitivity is usually programmed to the minimum value that reliably senses intrinsic cardiac activity. • PACING THRESHOLD: The minimum electrical energy required to consistently capture (depolarize) the myocardium. Set to 2-3 times the threshold to ensure adequate safety margin. • PULSE WIDTH AND AMPLITUDE: The duration and voltage of the pacing impulse; increased to ensure adequate capture. PACEMAKER MALFUNCTION: Two main types of malfunction: 1. FAILURE TO CAPTURE: • ECG finding: Pacing spike is NOT followed by a QRS complex (atrial or ventricular, depending on which chamber is involved) • Meaning: The pacemaker is firing (delivering an impulse) but the myocardium is not responding (not depolarizing) • Causes: - Lead dislodgement: The tip of the lead has moved away from the myocardium and is no longer in contact with viable myocardium - Lead fracture: The insulation or conductor is damaged, preventing current from reaching the tip - Increased pacing threshold: The myocardium is increasingly fibrotic or damaged and requires higher current to depolarize - Inadequate voltage/amplitude: The pacemaker is not delivering enough current - Battery depletion: The battery is too weak to deliver adequate current - Myocardial infarction: Necrotic tissue cannot be depolarized • Clinical consequence: If the pacemaker is the only source of rhythm (e.g., in complete heart block), loss of capture means loss of heart rate and symptoms of bradycardia (syncope, hypotension, altered consciousness, cardiac arrest) • ECG pattern: Pacing spikes on the monitor at the programmed rate, but no QRS complexes following the spikes (for ventricular pacing, no QRS; for atrial pacing, no P wave after the spike) • Action: If this occurs, immediately notify the provider; a temporary pacemaker or transcutaneous pacing may be needed; the permanent pacemaker will need urgent reprogramming or lead replacement 2. FAILURE TO SENSE: • ECG finding: The pacemaker fires (issues a pacing spike) when it should have sensed an intrinsic beat and been inhibited • Meaning: The pacemaker failed to detect an intrinsic cardiac impulse and inappropriately paced on top of the intrinsic beat • Types: - Oversensing: The pacemaker senses inappropriate signals (muscle artifact, external electromagnetic interference, T wave) and inhibits pacing when it should have paced. This causes symptomatic bradycardia. - Undersensing: The pacemaker does not sense intrinsic cardiac activity (amplitude of intrinsic beat is too low, sensitivity is set too low, lead malposition) and paces on top of the intrinsic beat • Clinical consequences: - Competitive pacing: Pacemaker spikes occur at regular intervals regardless of intrinsic cardiac activity. If a pacemaker spike lands on the T wave (vulnerable period of repolarization), it can trigger VF (called 'R-on-T phenomenon'). - Loss of pacing output if oversensing • ECG pattern: - Failure to sense intrinsic beats: Pacing spikes marching through the QRS complex, T wave, or PR interval (competitive pacing) - Oversensing: Absence of pacing spikes for prolonged periods, revealing slow or absent intrinsic rhythm • Action: Immediately notify the provider; a temporary pacemaker may be placed; the permanent pacemaker will need reprogramming or lead replacement NURSING MANAGEMENT OF TEMPORARY PACEMAKERS: 1. TRANSCUTANEOUS PACEMAKER: • Placement: Two adhesive pacing pads (negative on left anterior chest, positive on left midaxillary line). Pads should be on clean, dry skin; shave if very hairy. • Settings: Set the pacemaker unit to demand mode (not fixed rate), set the rate (usually 60-80 bpm), and set the milliamperage (mA) starting at 0 and increasing gradually while observing the monitor for electrical and mechanical capture. • Electrical capture: A pacing spike appears on the monitor before each QRS complex. • Mechanical capture: A palpable pulse (carotid or femoral) is present with each paced beat; check BP; use the femoral pulse if there is any doubt (avoid assessing brachial pulse as muscle artifact can mimic a pulse). • Once captured, increase the mA by 2-5 mA above the capture threshold (to ensure adequate safety margin). Typical range is 50-100 mA. • Pain management: Conscious patients experience significant discomfort (electrical stimulation of chest wall muscles); provide sedation (IV midazolam, propofol) and analgesia (IV morphine, fentanyl) as needed. • Monitoring: Continuous cardiac monitor; document rate, rhythm, presence of capture, and patient response. Assess for loss of capture (sudden absence of pulse despite continued pacing spikes). • Complications: Skin burns under pads (from prolonged pacing), failure to capture (see above), discomfort, muscle twitching, patient inability to tolerate if conscious • Temporal measure: Transcutaneous pacing is a bridge to more definitive therapy (transvenous pacemaker, medications, addressing underlying cause) and usually is maintained for hours to days at most 2. TRANSVENOUS PACEMAKER: • Placement: Usually done in the ICU or catheterization lab by a cardiologist or critical care specialist. Pacing catheter placed via central vein (usually right internal jugular or subclavian) into the right heart. • X-ray confirmation: CXR or fluoroscopy confirms catheter tip position in the right atrium and/or right ventricle • External pulse generator: Connected to the pacing catheter(s); placed on a stand beside the bed or worn on a belt • Settings: Similar to permanent pacemaker; programmed via an external programmer • Monitoring: Continuous cardiac monitoring; daily assessment of electrical and mechanical capture; assess for loss of capture • Line care: Strict sterile technique at the catheter insertion site; keep the site dry and covered with a sterile dressing; monitor for signs of infection (erythema, purulence, fever) • Lead dislodgement: Immobilize the patient's affected arm (if the catheter is in the internal jugular or subclavian, this is the ipsilateral arm) to prevent migration of the lead. Use an arm sling or restraint if needed. • Complications: Infection, catheter migration, perforation of the RV (can cause pericarditis/tamponade), pneumothorax (if subclavian approach), lead fracture, thrombosis of the vein • Duration: Can be maintained for weeks; eventually, if long-term pacing is needed, a permanent pacemaker is placed NURSING MANAGEMENT OF PERMANENT PACEMAKERS: 1. IMMEDIATE POST-IMPLANTATION (FIRST 1-2 WEEKS): • Wound care: Keep the incision clean and dry; change the dressing per protocol; monitor for signs of infection (erythema, warmth, purulent drainage, fever) • Activity restriction: Limit arm movement on the side of the pacemaker (affected arm) for 4-6 weeks to prevent lead dislodgement. Patient should not raise the arm above shoulder height. • Arm sling: May be recommended for the first 1-2 weeks to immobilize the arm. • Analgesia: Incisional pain is common; provide analgesics as needed • Chest X-ray: Obtained to confirm lead positions • ECG: Obtained post-implantation to document capture and baseline rhythm • Patient education: - Explain the pacemaker and why it was placed - Teach about activity restrictions and when they can resume normal activities (usually 4-6 weeks) - Explain that the pacemaker is not felt most of the time but may be perceived as a bump or mass under the skin - Discuss signs of infection to report immediately (fever, redness, swelling, drainage at the incision site) - Discuss signs of pacemaker malfunction to report (dizziness, syncope, palpitations, sudden hiccups—a rare sign of pacemaker lead perforating the RV and stimulating the diaphragm) 2. LONG-TERM MANAGEMENT: • Pulse checks: Teach the patient to check their pulse daily (at the wrist carotid artery) and report if the heart rate is below the set rate (e.g., if programmed to 60 bpm, report if resting HR is <60). A rate slower than the lower rate limit may indicate pacemaker malfunction or battery depletion. • Electromagnetic interference: The pacemaker may be affected by strong electromagnetic fields. Advise: - MRI: Generally contraindicated UNLESS the pacemaker is labeled "MRI-conditional" (certain newer models). Check the pacemaker identification card or medical record for compatibility. If MRI is necessary and the device is NOT MRI-safe, the pacemaker can be temporarily reprogrammed to a safe mode, the MRI performed, and then the device reprogrammed to the original settings. - Arc welding: Avoid; intense electromagnetic fields can interfere with pacemaker function - Strong magnets: Avoid (industrial magnets, metal detectors should not be held directly over the device) - Microwave ovens, cell phones, televisions, computers, and most household appliances: Safe if kept a reasonable distance (>6 inches) from the device. Most modern devices are well-shielded. - Metal detectors at airports and security checkpoints: Will alarm; patient should show the pacemaker identification card to security personnel. Handheld metal detector wands should not be held directly over the device; the patient can be patted down instead. - Cellular telephones: Use on the ear opposite the pacemaker; keep >6 inches from the device - Diathermy and shortwave therapy: Contraindicated; can reprogram the pacemaker or cause heating of the lead • Pacemaker identification card: Patient should carry at all times; includes pacemaker model, settings, implant date, and cardiologist contact information • Regular follow-up: Patient should see the cardiologist every 3-6 months for pacemaker checks (in-office checks) and every 3-5 years for pacemaker replacement (when battery is depleted). The old device is removed, a new device is inserted, and the leads may be reused if they are still functional or replaced if damaged. • Remote monitoring: Many newer pacemakers have remote monitoring capability, allowing the device to transmit data wirelessly to the cardiologist's office. This reduces the need for in-person visits and allows early detection of device malfunction, battery issues, or rhythm changes. • Medications: Continue taking all cardiac medications (beta-blockers, ACEi, diuretics, etc.) unless the pacemaker function has changed the need for them. Some patients with SSS can reduce or stop beta-blockers after pacemaker placement if they previously needed them for rate control. • Driving: Patient can usually resume driving once cleared by the cardiologist (typically 1-2 weeks post-implantation). Some restrictions apply in certain countries; in the Philippines, patients should clarify with the Land Transportation Office. • Pregnancy: Pregnancy is not contraindicated in women with pacemakers. Pregnant patients should be monitored closely; pacemaker checks may be needed more frequently during pregnancy. • Dental and surgical procedures: Routine dental work and non-cardiac surgery can be performed in patients with pacemakers. Inform the dentist or surgeon of the pacemaker and ensure continuity of care; elective procedures should be postponed if the battery is near depletion (last replacement >5 years ago). Cautery (electrosurgical units) used during surgery can interfere; the pacemaker should be placed in a safe mode or inactivated, then reprogrammed after the procedure. • Life expectancy: Pacemaker placement does not significantly reduce life expectancy; the pacemaker is expected to function for 7-15 years depending on use and current drain 3. COMPLICATIONS: • Infection: Pacemaker site infection or sepsis; may require removal of the device, IV antibiotics, and later reimplantation • Lead migration or fracture: Loss of capture; may require lead repositioning or replacement • Pericarditis or tamponade: If the lead perforates the RV; presents with chest pain, pulsus paradoxus, elevated JVD; requires urgent intervention • Twiddler's syndrome: Patient unconsciously manipulates the pacemaker under the skin, rotating the pulse generator and causing lead dislodgement; loss of capture results; requires surgical correction and sometimes behavioral intervention • Allergic reaction: To the pacemaker material (rare); may require removal or hypoallergenic device • Syncope due to pacemaker syndrome: Occurs in some patients (usually those with VVI pacing) when the pacemaker fires but the patient's intrinsic atrial activity is not synchronized; the patient loses the 'atrial kick' at times, reducing cardiac output and causing syncope. Treated by upgrading to a dual-chamber pacemaker (DDD) that restores AV synchronization